Selected research
Industry Research
Dystrophin Industry Research Report 2026
Market perspective
The global Dystrophin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dystrophin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dystrophin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dystrophin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dystrophin include Pfizer Inc, Daiichi Sankyo Company Ltd, WAVE Life Sciences Ltd, Sarepta Therapeutics Inc, Nippon Shinyaku Co Ltd, Genethon SA, Editas Medicine Inc, BioMarin Pharmaceutical Inc and Asklepios BioPharmaceutical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dystrophin market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dystrophin Market by Company
Pfizer Inc
Daiichi Sankyo Company Ltd
WAVE Life Sciences Ltd
Sarepta Therapeutics Inc
Nippon Shinyaku Co Ltd
Genethon SA
Editas Medicine Inc
BioMarin Pharmaceutical Inc
Asklepios BioPharmaceutical Inc
Dystrophin Segment by Type
DS-5141
Biostrophin
BMBD-001
NS-065
Others
Dystrophin Segment by Application
Genetic Disorders
Musculoskeletal Disorders
Others
Dystrophin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dystrophin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dystrophin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dystrophin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dystrophin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dystrophin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dystrophin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DS-5141
- Biostrophin
- BMBD-001
- NS-065
- Others
Applications
- Genetic Disorders
- Musculoskeletal Disorders
- Others
Companies covered
- Pfizer Inc
- Daiichi Sankyo Company Ltd
- WAVE Life Sciences Ltd
- Sarepta Therapeutics Inc
- Nippon Shinyaku Co Ltd
- Genethon SA
- Editas Medicine Inc
- BioMarin Pharmaceutical Inc
- Asklepios BioPharmaceutical Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dystrophin Market Size (2021-2032)
- 2.2.2 Global Dystrophin Sales (2021-2032)
- 2.2.3 Global Dystrophin Market Average Price (2021-2032)
- 2.3 Dystrophin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DS-5141
- 2.3.3 Biostrophin
- 2.3.4 BMBD-001
- 2.3.5 NS-065
- 2.3.6 Others
- 2.4 Dystrophin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Genetic Disorders
- 2.4.3 Musculoskeletal Disorders
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dystrophin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dystrophin Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Dystrophin Revenue of Manufacturers (2021-2026)
- 3.4 Global Dystrophin Average Price by Manufacturers (2021-2026)
- 3.5 Global Dystrophin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dystrophin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dystrophin, Product Type & Application
- 3.8 Global Manufacturers of Dystrophin, Established Date
- 3.9 Global Dystrophin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer Inc
- 4.1.1 Pfizer Inc Company Information
- 4.1.2 Pfizer Inc Business Overview
- 4.1.3 Pfizer Inc Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Inc Dystrophin Product Portfolio
- 4.1.5 Pfizer Inc Recent Developments
- 4.2 Daiichi Sankyo Company Ltd
- 4.2.1 Daiichi Sankyo Company Ltd Company Information
- 4.2.2 Daiichi Sankyo Company Ltd Business Overview
- 4.2.3 Daiichi Sankyo Company Ltd Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Daiichi Sankyo Company Ltd Dystrophin Product Portfolio
- 4.2.5 Daiichi Sankyo Company Ltd Recent Developments
- 4.3 WAVE Life Sciences Ltd
- 4.3.1 WAVE Life Sciences Ltd Company Information
- 4.3.2 WAVE Life Sciences Ltd Business Overview
- 4.3.3 WAVE Life Sciences Ltd Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 WAVE Life Sciences Ltd Dystrophin Product Portfolio
- 4.3.5 WAVE Life Sciences Ltd Recent Developments
- 4.4 Sarepta Therapeutics Inc
- 4.4.1 Sarepta Therapeutics Inc Company Information
- 4.4.2 Sarepta Therapeutics Inc Business Overview
- 4.4.3 Sarepta Therapeutics Inc Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sarepta Therapeutics Inc Dystrophin Product Portfolio
- 4.4.5 Sarepta Therapeutics Inc Recent Developments
- 4.5 Nippon Shinyaku Co Ltd
- 4.5.1 Nippon Shinyaku Co Ltd Company Information
- 4.5.2 Nippon Shinyaku Co Ltd Business Overview
- 4.5.3 Nippon Shinyaku Co Ltd Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nippon Shinyaku Co Ltd Dystrophin Product Portfolio
- 4.5.5 Nippon Shinyaku Co Ltd Recent Developments
- 4.6 Genethon SA
- 4.6.1 Genethon SA Company Information
- 4.6.2 Genethon SA Business Overview
- 4.6.3 Genethon SA Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genethon SA Dystrophin Product Portfolio
- 4.6.5 Genethon SA Recent Developments
- 4.7 Editas Medicine Inc
- 4.7.1 Editas Medicine Inc Company Information
- 4.7.2 Editas Medicine Inc Business Overview
- 4.7.3 Editas Medicine Inc Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Editas Medicine Inc Dystrophin Product Portfolio
- 4.7.5 Editas Medicine Inc Recent Developments
- 4.8 BioMarin Pharmaceutical Inc
- 4.8.1 BioMarin Pharmaceutical Inc Company Information
- 4.8.2 BioMarin Pharmaceutical Inc Business Overview
- 4.8.3 BioMarin Pharmaceutical Inc Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BioMarin Pharmaceutical Inc Dystrophin Product Portfolio
- 4.8.5 BioMarin Pharmaceutical Inc Recent Developments
- 4.9 Asklepios BioPharmaceutical Inc
- 4.9.1 Asklepios BioPharmaceutical Inc Company Information
- 4.9.2 Asklepios BioPharmaceutical Inc Business Overview
- 4.9.3 Asklepios BioPharmaceutical Inc Dystrophin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Asklepios BioPharmaceutical Inc Dystrophin Product Portfolio
- 4.9.5 Asklepios BioPharmaceutical Inc Recent Developments
5 Global Dystrophin Market Scenario by Region
- 5.1 Global Dystrophin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dystrophin Sales by Region: 2021-2032
- 5.2.1 Global Dystrophin Sales by Region: 2021-2026
- 5.2.2 Global Dystrophin Sales by Region: 2027-2032
- 5.3 Global Dystrophin Revenue by Region: 2021-2032
- 5.3.1 Global Dystrophin Revenue by Region: 2021-2026
- 5.3.2 Global Dystrophin Revenue by Region: 2027-2032
- 5.4 North America Dystrophin Market Facts & Figures by Country
- 5.4.1 North America Dystrophin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dystrophin Sales by Country (2021-2032)
- 5.4.3 North America Dystrophin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dystrophin Market Facts & Figures by Country
- 5.5.1 Europe Dystrophin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dystrophin Sales by Country (2021-2032)
- 5.5.3 Europe Dystrophin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dystrophin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dystrophin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dystrophin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dystrophin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dystrophin Market Facts & Figures by Country
- 5.7.1 South America Dystrophin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dystrophin Sales by Country (2021-2032)
- 5.7.3 South America Dystrophin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dystrophin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dystrophin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dystrophin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dystrophin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dystrophin Sales by Type (2021-2032)
- 6.1.1 Global Dystrophin Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Dystrophin Sales Market Share by Type (2021-2032)
- 6.2 Global Dystrophin Revenue by Type (2021-2032)
- 6.2.1 Global Dystrophin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dystrophin Revenue Market Share by Type (2021-2032)
- 6.3 Global Dystrophin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dystrophin Sales by Application (2021-2032)
- 7.1.1 Global Dystrophin Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Dystrophin Sales Market Share by Application (2021-2032)
- 7.2 Global Dystrophin Revenue by Application (2021-2032)
- 7.2.1 Global Dystrophin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dystrophin Revenue Market Share by Application (2021-2032)
- 7.3 Global Dystrophin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dystrophin Value Chain Analysis
- 8.1.1 Dystrophin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dystrophin Production Mode & Process
- 8.2 Dystrophin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dystrophin Distributors
- 8.2.3 Dystrophin Customers
9 Global Dystrophin Analyzing Market Dynamics
- 9.1 Dystrophin Industry Trends
- 9.2 Dystrophin Industry Drivers
- 9.3 Dystrophin Industry Opportunities and Challenges
- 9.4 Dystrophin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst